Erasca (ERAS) Other Gross PP&E Adjustments (2020 - 2026)
Erasca posted quarterly Other Gross PP&E Adjustments of -$2.8 million for Q1 2026, up 48.82% year-on-year from -$1.9 million in Q1 2025, and up 16.25% on a QoQ basis from -$3.3 million in Q4 2025.
Erasca (ERAS) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 48.82% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$2.8 million (up 48.82% YoY), and the FY2025 full-year result was -$3.3 million, up 74.38% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$2.8 million, up from -$3.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $10.7 million in Q2 2022 and bottomed at -$16.1 million in Q4 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$7.7 million (2024), against an average of -$6.7 million.
- Peak annual rise in Other Gross PP&E Adjustments reached 850.13% in 2022, while the deepest fall reached 2516.29% in 2022.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$16.1 million in 2022, then grew by 23.38% to -$12.3 million in 2023, then dropped by 4.59% to -$12.9 million in 2024, then surged by 74.38% to -$3.3 million in 2025, then rose by 16.25% to -$2.8 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$2.8 million (Q1 2026), -$3.3 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -2.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.76 Mn |
| Mar 31, 2026 | -2.76 Mn |
| Dec 31, 2025 | -3.30 Mn |
| Dec 31, 2025 | -3.30 Mn |
| Sep 30, 2025 | -4.55 Mn |
| Sep 30, 2025 | -4.55 Mn |
| Jun 30, 2025 | -4.90 Mn |
| Jun 30, 2025 | -4.90 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Dec 31, 2024 | -12.87 Mn |
| Dec 31, 2024 | -12.87 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -7.73 Mn |
| Jun 30, 2024 | -7.73 Mn |
| Mar 31, 2024 | -8.22 Mn |
| Mar 31, 2024 | -8.22 Mn |
| Dec 31, 2023 | -12.31 Mn |
| Dec 31, 2023 | -12.31 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -10.49 Mn |
| Jun 30, 2023 | -10.49 Mn |
| Mar 31, 2023 | -11.12 Mn |
| Mar 31, 2023 | -11.12 Mn |
| Dec 31, 2022 | -16.06 Mn |
| Dec 31, 2022 | -16.06 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | 10.75 Mn |
| Jun 30, 2022 | 10.75 Mn |
| Mar 31, 2022 | 5.40 Mn |
| Mar 31, 2022 | 5.40 Mn |
| Dec 31, 2021 | -614,000.00 |
| Dec 31, 2021 | -614,000.00 |
| Sep 30, 2021 | -9.29 Mn |
| Sep 30, 2021 | -9.29 Mn |
| Jun 30, 2021 | 1.13 Mn |
| Jun 30, 2021 | 1.13 Mn |
| Dec 31, 2020 | 330,000.00 |
| Dec 31, 2020 | 330,000.00 |